Fig. 2.
Befiradol does not alleviate DAMGO-induced respiratory depression in vitro. A representative rectified and integrated recording of the respiratory discharge of fourth cervical ventral nerve roots (C4) produced by a postnatal day (P) 3 brainstem–spinal cord preparation in (A) control, (B) with bath application of DAMGO (300 nM), and (C) subsequent bath application of befiradol (10 μM) in the continued presence of DAMGO (300 nM). (D) Population data with brainstem–spinal cord (300 nM DAMGO, 1 to 30 μM befiradol, n = 6 each) or medullary slice (300 nM DAMGO, 3 to 30 μM befiradol, n = 5 each). There is no significant difference in respiratory frequency after befiradol using one-way repeated-measures ANOVA (Tukey method). DAMGO = D-Ala2, N-MePhe4, Gly-ol-enkephalin.

Befiradol does not alleviate DAMGO-induced respiratory depression in vitro. A representative rectified and integrated recording of the respiratory discharge of fourth cervical ventral nerve roots (C4) produced by a postnatal day (P) 3 brainstem–spinal cord preparation in (A) control, (B) with bath application of DAMGO (300 nM), and (C) subsequent bath application of befiradol (10 μM) in the continued presence of DAMGO (300 nM). (D) Population data with brainstem–spinal cord (300 nM DAMGO, 1 to 30 μM befiradol, n = 6 each) or medullary slice (300 nM DAMGO, 3 to 30 μM befiradol, n = 5 each). There is no significant difference in respiratory frequency after befiradol using one-way repeated-measures ANOVA (Tukey method). DAMGO = D-Ala2, N-MePhe4, Gly-ol-enkephalin.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal